247 related articles for article (PubMed ID: 21715007)
1. Measurement and rates of persistence with and adherence to biologics for rheumatoid arthritis: a systematic review.
Blum MA; Koo D; Doshi JA
Clin Ther; 2011 Jul; 33(7):901-13. PubMed ID: 21715007
[TBL] [Abstract][Full Text] [Related]
2. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.
Lyu R; Govoni M; Ding Q; Black CM; Kachroo S; Fan T; Ogbonnaya A; Donga P; Hill J; Makin C
Rheumatol Int; 2016 Jan; 36(1):143-53. PubMed ID: 26314368
[TBL] [Abstract][Full Text] [Related]
3. Adherence and Persistence with Methotrexate in Rheumatoid Arthritis: A Systematic Review.
Curtis JR; Bykerk VP; Aassi M; Schiff M
J Rheumatol; 2016 Nov; 43(11):1997-2009. PubMed ID: 27803341
[TBL] [Abstract][Full Text] [Related]
4. Persistence of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: An analysis of the South Korean National Health Insurance Database.
Lee MY; Shin JY; Park SY; Kim D; Cha HS; Lee EK
Semin Arthritis Rheum; 2018 Feb; 47(4):485-491. PubMed ID: 28939234
[TBL] [Abstract][Full Text] [Related]
5. Influence of route of administration/drug formulation and other factors on adherence to treatment in rheumatoid arthritis (pain related) and dyslipidemia (non-pain related).
Fautrel B; Balsa A; Van Riel P; Casillas M; Capron JP; Cueille C; de la Torre I
Curr Med Res Opin; 2017 Jul; 33(7):1231-1246. PubMed ID: 28358217
[TBL] [Abstract][Full Text] [Related]
6. Impact of physicians' adherence to treat-to-target strategy on outcomes in early rheumatoid arthritis in the NEO-RACo trial.
Kuusalo L; Puolakka K; Kautiainen H; Blåfield H; Eklund KK; Ilva K; Kaipiainen-Seppänen O; Karjalainen A; Korpela M; Valleala H; Leirisalo-Repo M; Rantalaiho V;
Scand J Rheumatol; 2015; 44(6):449-55. PubMed ID: 26324784
[TBL] [Abstract][Full Text] [Related]
7. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
Markenson JA; Gibofsky A; Palmer WR; Keystone EC; Schiff MH; Feng J; Baumgartner SW
J Rheumatol; 2011 Jul; 38(7):1273-81. PubMed ID: 21572150
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and drug adherence of biologic monotherapy in routine care of patients with rheumatoid arthritis: a cohort study of patients registered in the Danish biologics registry.
Jørgensen TS; Kristensen LE; Christensen R; Bliddal H; Lorenzen T; Hansen MS; Østergaard M; Jensen J; Zanjani L; Laursen T; Butt S; Dam MY; Lindegaard HM; Espesen J; Hendricks O; Kumar P; Kincses A; Larsen LH; Andersen M; Næser EK; Jensen DV; Grydehøj J; Unger B; Dufour N; Sørensen V; Vildhøj S; Hansen IM; Raun J; Krogh NS; Hetland ML
Rheumatology (Oxford); 2015 Dec; 54(12):2156-65. PubMed ID: 26175471
[TBL] [Abstract][Full Text] [Related]
9. Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review.
Murage MJ; Tongbram V; Feldman SR; Malatestinic WN; Larmore CJ; Muram TM; Burge RT; Bay C; Johnson N; Clifford S; Araujo AB
Patient Prefer Adherence; 2018; 12():1483-1503. PubMed ID: 30174415
[TBL] [Abstract][Full Text] [Related]
10. Adherence, discontinuation, and switching of biologic therapies in medicaid enrollees with rheumatoid arthritis.
Li P; Blum MA; Von Feldt J; Hennessy S; Doshi JA
Value Health; 2010; 13(6):805-12. PubMed ID: 21054657
[TBL] [Abstract][Full Text] [Related]
11. Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis.
Grijalva CG; Chung CP; Arbogast PG; Stein CM; Mitchel EF; Griffin MR
Med Care; 2007 Oct; 45(10 Supl 2):S66-76. PubMed ID: 17909386
[TBL] [Abstract][Full Text] [Related]
12. Estimating effectiveness and cost of biologics for rheumatoid arthritis: application of a validated algorithm to commercial insurance claims.
Curtis JR; Schabert VF; Harrison DJ; Yeaw J; Korn JR; Quach C; Yun H; Joseph GJ; Collier DH
Clin Ther; 2014 Jul; 36(7):996-1004. PubMed ID: 25012729
[TBL] [Abstract][Full Text] [Related]
13. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.
Carter CT; Changolkar AK; Scott McKenzie R
J Med Econ; 2012; 15(2):332-9. PubMed ID: 22168788
[TBL] [Abstract][Full Text] [Related]
14. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.
Hetland ML; Christensen IJ; Tarp U; Dreyer L; Hansen A; Hansen IT; Kollerup G; Linde L; Lindegaard HM; Poulsen UE; Schlemmer A; Jensen DV; Jensen S; Hostenkamp G; Østergaard M;
Arthritis Rheum; 2010 Jan; 62(1):22-32. PubMed ID: 20039405
[TBL] [Abstract][Full Text] [Related]
15. Cost per patient-year in response using a claims-based algorithm for the 2 years following biologic initiation in patients with rheumatoid arthritis.
Bonafede M; Johnson BH; Princic N; Shah N; Harrison DJ
J Med Econ; 2015 May; 18(5):376-89. PubMed ID: 25530318
[TBL] [Abstract][Full Text] [Related]
16. Discontinuation, persistence and adherence to subcutaneous biologics delivered via a homecare route to Scottish adults with rheumatic diseases: a retrospective study.
Alvarez-Madrazo S; Kavanagh K; Siebert S; Semple Y; Godman B; Maciel Almeida A; Acurcio FA; Bennie M
BMJ Open; 2019 Sep; 9(9):e027059. PubMed ID: 31488467
[TBL] [Abstract][Full Text] [Related]
17. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis.
Finckh A; Bansback N; Marra CA; Anis AH; Michaud K; Lubin S; White M; Sizto S; Liang MH
Ann Intern Med; 2009 Nov; 151(9):612-21. PubMed ID: 19884622
[TBL] [Abstract][Full Text] [Related]
18. Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis.
Wu E; Chen L; Birnbaum H; Yang E; Cifaldi M
Curr Med Res Opin; 2008 Aug; 24(8):2229-40. PubMed ID: 18577308
[TBL] [Abstract][Full Text] [Related]
19. Medication Persistence of Disease-Modifying Antirheumatic Drugs and Anti-Tumor Necrosis Factor Agents in a Cohort of Patients With Rheumatoid Arthritis in Brazil.
Acurcio FA; Machado MA; Moura CS; Ferre F; Guerra AA; Andrade EI; Cherchiglia ML; Rahme E
Arthritis Care Res (Hoboken); 2016 Oct; 68(10):1489-96. PubMed ID: 26814681
[TBL] [Abstract][Full Text] [Related]
20. Medication adherence and persistence in the treatment of rheumatoid arthritis with adalimumab and etanercept. Six years of analysis.
Santoleri F; Sorice P; Lasala R; Rizzo RC; Costantini A
J Med Econ; 2014 May; 17(5):320-5. PubMed ID: 24641160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
